Patents by Inventor Paul N. MUDD, Jr.
Paul N. MUDD, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957684Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: July 15, 2022Date of Patent: April 16, 2024Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Patent number: 11918583Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: July 15, 2022Date of Patent: March 5, 2024Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Publication number: 20240050457Abstract: The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a patient in need thereof a therapeutically effective amount of vibegron, wherein the patient is concomitantly receiving digoxin, wherein the patient's digoxin serum level is maintained at an amount that results in a desired digoxin clinical effect. This can be achieved by monitoring the patient's digoxin serum level before, during, and/or after vibegron treatment, and either maintaining or titrating the digoxin dose based on that level to achieve the desired clinical effect.Type: ApplicationFiled: December 22, 2021Publication date: February 15, 2024Inventor: Paul N. MUDD, Jr.
-
Patent number: 11793812Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: May 11, 2021Date of Patent: October 24, 2023Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Patent number: 11583526Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 20, 2020Date of Patent: February 21, 2023Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company LimitedInventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. MacLean, Lynn Seely, Paul N. Mudd, Jr.
-
Publication number: 20230027066Abstract: The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of 75 mg of vibegron per day.Type: ApplicationFiled: March 18, 2020Publication date: January 26, 2023Applicant: Urovant Sciences GmbHInventor: Paul N. MUDD, Jr.
-
Publication number: 20220401443Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 15, 2022Publication date: December 22, 2022Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JOHNSON, David B. MACLEAN, Lynn SEELY, Paul N. MUDD, JR.
-
Publication number: 20220370462Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: ApplicationFiled: July 15, 2022Publication date: November 24, 2022Inventors: Brendan Mark JOHNSON, Lynn SEELY, Paul N. MUDD, JR., Susan WOLLOWITZ, Mark HIBBERD, Masataka TANIMOTO, Vijaykumar Reddy RAJASEKHAR, Mayukh Vasant SUKHATME
-
Publication number: 20220117971Abstract: The present disclosure is directed to a method of treating overactive bladder symptoms in men with benign prostatic hyperplasia comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day.Type: ApplicationFiled: December 5, 2019Publication date: April 21, 2022Applicant: Urovant Sciences GmbHInventors: Paul N. MUDD, Jr., Cornelia HAAG-MOLKENTELLER, Jihao ZHOU
-
Publication number: 20210401841Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: ApplicationFiled: May 11, 2021Publication date: December 30, 2021Inventors: Brendan Mark JOHNSON, Lynn SEELY, Paul N. MUDD, JR., Susan WOLLOWITZ, Mark HIBBERD, Masataka TANIMOTO, Vijaykumar Reddy RAJASEKHAR, Mayukh Vasant SUKHATME
-
Publication number: 20210205303Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 20, 2020Publication date: July 8, 2021Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JOHNSON, David B. MacLEAN, Lynn SEELY, Paul N. MUDD, JR.
-
Publication number: 20210196720Abstract: The present disclosure is directed to a method of treating or preventing pain associated with irritable bowel syndrome comprising orally administering to a subject in need thereof vibegron.Type: ApplicationFiled: May 23, 2019Publication date: July 1, 2021Applicant: UROVANT SCIENCES GMBHInventors: Paul N. MUDD, JR., Cornelia HAAG-MOLKENTELLER, Jihao ZHOU, Chris SCHAUMBURG, Jean Paul Abrian NICANDRO
-
Patent number: 11033551Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: March 29, 2019Date of Patent: June 15, 2021Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Patent number: 10786501Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 6, 2019Date of Patent: September 29, 2020Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company LimitedInventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. MacLean, Lynn Seely, Paul N. Mudd, Jr.
-
Publication number: 20200129507Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 6, 2019Publication date: April 30, 2020Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JOHNSON, David B. MacLEAN, Lynn SEELY, Paul N. MUDD, JR.
-
Patent number: 10449191Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 29, 2019Date of Patent: October 22, 2019Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company LimitedInventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. MacLean, Lynn Seely, Paul N. Mudd, Jr.
-
Publication number: 20190262346Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: ApplicationFiled: March 29, 2019Publication date: August 29, 2019Inventors: Brendan Mark JOHNSON, Lynn SEELY, Paul N. MUDD, JR., Susan WOLLOWITZ, Mark HIBBERD, Masataka TANIMOTO, Vijaykumar Reddy RAJASEKHAR, Mayukh Vasant SUKHATME
-
Publication number: 20190224196Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 29, 2019Publication date: July 25, 2019Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JOHNSON, David B. MacLEAN, Lynn SEELY, Paul N. MUDD, Jr.